Aprea to present Phase 1 data on APR-1051 at EORTC-NCI-AACR symposium

September 22, 2026 8:30 AM

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that updated interim results from its ongoing Phase 1 ACESOT-1051 study of WEE1 inhibitor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found